Achievement of Three Year Remission with Bevacizumab and Irinotecan in Recurrent Glioblastoma Multiforme: A case Report

Abstract

A 34-year-old man presented to the hospital with right-sided headache. He was diagnosed with GBM. He underwent resection of the tumor with placement of carmustine impregnated wafers. Then he underwent adjuvant chemotherapy with temozolamide. Before the completion of chemotherapy he had a recurrence. He underwent re-resection with placement of carmustine impregnated wafers. Subsequently he had eighteen cycles of salvage biochemotherapy with bevacizumab and irinotecan. To date, routine MRI scans of the brain have not shown evidence of recurrence. He continues to be in remission three years after treatment with bevacizumab and irinotecan.

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

“…There are few reports of long-term surviving recurrent high- and low-grade glioma patients who have had prolonged survival [13–17], but these studies do not specifically focus on these long-term surviving patients, especially in the context of Bev. For recurrent GBM patients treated with Bev, two case reports each described a patient achieving tumor-free status at 26 months and 3 years, respectively, with the latter patient receiving surgical re-resection and irinotecan in conjunction with Bev [18,19]. A retrospective analysis of Bev treatment in a cohort of 16 recurrent GBM patients showed a median post-progression survival of 39.6 months [20].…”